[go: up one dir, main page]

MA58049B1 - Antagonistes du récepteur du sous-type 2 de la mélanocortine (mc2r) à pipéridine à double substitution gem et leurs utilisations - Google Patents

Antagonistes du récepteur du sous-type 2 de la mélanocortine (mc2r) à pipéridine à double substitution gem et leurs utilisations

Info

Publication number
MA58049B1
MA58049B1 MA58049A MA58049A MA58049B1 MA 58049 B1 MA58049 B1 MA 58049B1 MA 58049 A MA58049 A MA 58049A MA 58049 A MA58049 A MA 58049A MA 58049 B1 MA58049 B1 MA 58049B1
Authority
MA
Morocco
Prior art keywords
mc2r
receptor
gem
antagonists
double
Prior art date
Application number
MA58049A
Other languages
English (en)
Inventor
Yunfei Zhu
Sangdon Han
Sun Hee Kim
Original Assignee
Crinetics Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crinetics Pharmaceuticals, Inc. filed Critical Crinetics Pharmaceuticals, Inc.
Publication of MA58049B1 publication Critical patent/MA58049B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des composés qui sont des modulateurs du récepteur du sous-type 2 de la mélanocortine (MC2R), des procédés de préparation de tels composés, des compositions pharmaceutiques et des médicaments comprenant de tels composés, ainsi que des méthodes d'utilisation de tels composés dans le traitement d'affections, de maladies ou de troubles qui pourraient bénéficier de la modulation de l'activité de MC2R.
MA58049A 2019-12-18 2020-12-11 Antagonistes du récepteur du sous-type 2 de la mélanocortine (mc2r) à pipéridine à double substitution gem et leurs utilisations MA58049B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962949854P 2019-12-18 2019-12-18
EP20903163.2A EP4077307B1 (fr) 2019-12-18 2020-12-11 Antagonistes du récepteur du sous-type 2 de la mélanocortine (mc2r) à pipéridine à double substitution gem et leurs utilisations
PCT/US2020/064493 WO2021126693A1 (fr) 2019-12-18 2020-12-11 Antagonistes du récepteur du sous-type 2 de la mélanocortine (mc2r) à pipéridine à double substitution gem et leurs utilisations

Publications (1)

Publication Number Publication Date
MA58049B1 true MA58049B1 (fr) 2025-06-30

Family

ID=76477827

Family Applications (1)

Application Number Title Priority Date Filing Date
MA58049A MA58049B1 (fr) 2019-12-18 2020-12-11 Antagonistes du récepteur du sous-type 2 de la mélanocortine (mc2r) à pipéridine à double substitution gem et leurs utilisations

Country Status (20)

Country Link
US (1) US12492181B2 (fr)
EP (2) EP4556067A3 (fr)
JP (2) JP7672406B2 (fr)
KR (1) KR20220129553A (fr)
CN (1) CN115335369B (fr)
AU (1) AU2020407016A1 (fr)
BR (1) BR112022012033A2 (fr)
CA (1) CA3164117A1 (fr)
DK (1) DK4077307T3 (fr)
ES (1) ES3031394T3 (fr)
FI (1) FI4077307T3 (fr)
HU (1) HUE071813T2 (fr)
IL (2) IL293941B2 (fr)
MA (1) MA58049B1 (fr)
MD (1) MD4077307T2 (fr)
MX (1) MX2022007439A (fr)
PL (1) PL4077307T3 (fr)
PT (1) PT4077307T (fr)
SI (1) SI4077307T1 (fr)
WO (1) WO2021126693A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102695210B1 (ko) 2018-06-05 2024-08-13 크리네틱스 파마슈티칼스, 인크. 멜라노코르틴 아형-2 수용체(mc2r) 길항제 및 이의 용도
JP7657792B2 (ja) 2019-11-07 2025-04-07 クリネティックス ファーマシューティカルズ，インク． メラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用
PT4077307T (pt) 2019-12-18 2025-06-03 Crinetics Pharmaceuticals Inc Antagonistas do recetor de subtipo 2 da melanocortina (mc2r) à base de piperidina gem-dissubstituída e suas utilizações
US12466829B2 (en) 2019-12-23 2025-11-11 Crinetics Pharmaceuticals, Inc. Spirocyclic piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
JP2024510260A (ja) 2021-03-19 2024-03-06 クリネティックス ファーマシューティカルズ，インク． 疾患の治療のためのメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニスト
US20230405157A1 (en) * 2022-05-10 2023-12-21 Radionetics Oncology, Inc. Melanocortin type 2 receptor (mc2r) targeted therapeutics and uses thereof
IL322678A (en) 2023-02-23 2025-10-01 Omass Therapeutics Ltd MC2R modulator compounds
GB202302629D0 (en) 2023-02-23 2023-04-12 Omass Therapeutics Ltd MC2R modulator compounds
GB202302618D0 (en) 2023-02-23 2023-04-12 Omass Therapeutics Ltd MC2R modulator compounds

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2881750B2 (ja) 1988-09-06 1999-04-12 エフ・ホフマン‐ラ ロシユ アーゲー ２‐（２‐フルオロフエニル）‐ピリジン
US5284956A (en) 1988-09-06 1994-02-08 Hoffmann-La Roche Inc. Liquid crystalline mixtures containing 2-(2-fluorophenyl) pyridines
EE04746B1 (et) 1997-06-24 2006-12-15 Janssen Pharmaceutica N.V. 5-asendatud-1,2,4-tiadiasolüülderivaadid, nende valmistamismeetod, kasutamine, farmatseutiline kompositsioon, vaheühend ja selle valmistamismeetod
US6833369B2 (en) 1997-06-24 2004-12-21 Janssen Pharmaceutica, Nv Angiogenesis inhibiting 5-substituted-1,2,4,-thiadiazolyl derivatives
EP1085869A4 (fr) 1998-06-11 2001-10-04 Merck & Co Inc Derives de spiropiperidine en tant qu'agonistes des recepteurs de la melanocortine
JP2003505435A (ja) * 1999-06-04 2003-02-12 メルク エンド カムパニー インコーポレーテッド メラノコルチン−４受容体ゴニストとしての置換ピペリジン
US7208503B2 (en) 2000-04-21 2007-04-24 Janssen Pharmaceutica N.V. Angiogenesis inhibiting 5-substituted-1,2,4-thiadiazolyl derivatives
US7115607B2 (en) 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
US6977264B2 (en) 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
WO2003031410A1 (fr) 2001-10-09 2003-04-17 Neurocrine Biosciences, Inc. Ligands de recepteurs de la melanocortine et compositions et methodes associees
ATE446286T1 (de) * 2001-11-26 2009-11-15 Schering Corp Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität und störungen des zentralnervensystems
AU2003216274A1 (en) 2002-02-11 2003-09-04 Neurocrine Biosciences, Inc. Pyrrole derivatives as ligands of melanocortin receptors
EP1503761A1 (fr) 2002-05-10 2005-02-09 Neurocrine Biosciences, Inc. Utilisation de piperazines substituees comme ligands du recepteur de la melanocortine
WO2004081643A1 (fr) 2002-12-20 2004-09-23 Kaiser Aerospace & Electronics Corp. Reseau de lentilles a conversion de polarisation
EP1460073A1 (fr) 2003-03-20 2004-09-22 MyoContract Ltd. Dérivés substitués de la pipéridine et la pipérazine comme modulateurs du récepteur de la melanocortine-4
DK1656361T3 (da) 2003-08-11 2008-05-05 Hoffmann La Roche Piperazin med OR-substitueret phenylgruppe og anvendelse deraf som GLYT1-inhibitorer
BRPI0414209B8 (pt) 2003-09-09 2021-05-25 Hoffmann La Roche derivados de 1-(2-amino-benzol)-piperazina, seus processos de preparação e seu uso, e medicamento
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
WO2005040109A1 (fr) 2003-10-22 2005-05-06 Neurocrine Biosciences, Inc. Ligands du recepteur de la melanocortine et compositions et methodes associees
WO2005042516A2 (fr) 2003-10-22 2005-05-12 Neurocrine Biosciences, Inc. Ligands de recepteurs de la melanocortine, compositions et procedes associes
KR20050045927A (ko) * 2003-11-12 2005-05-17 주식회사 엘지생명과학 멜라노코틴 수용체의 항진제
PT1778236E (pt) 2004-07-02 2010-10-19 Corcept Therapeutics Inc Moduladores do receptor de glucocorticóide de pirimidina modificada
WO2006058294A2 (fr) 2004-11-29 2006-06-01 Vertex Pharmaceuticals Incorporated Modulateurs des recepteurs muscariniques
TW200716594A (en) 2005-04-18 2007-05-01 Neurogen Corp Substituted heteroaryl CB1 antagonists
AU2006247482A1 (en) * 2005-05-13 2006-11-23 Lexicon Pharmaceuticals, Inc. Multicyclic compounds and methods of their use
EP1940401B1 (fr) 2005-10-18 2012-07-11 Merck Sharp & Dohme Corp. Derives de spiropiperidine acyles utilises en tant que modulateurs vis-a-vis du recepteur de melanocortine-4
CN101374519A (zh) 2005-12-22 2009-02-25 弗特克斯药品有限公司 毒蕈碱性受体调节剂
JP2009534456A (ja) 2006-04-25 2009-09-24 アステックス、セラピューティックス、リミテッド 医薬化合物
EP2108641A1 (fr) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. Nouveaux dérivés substitués de spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one et leur utilisation comme ihibiteurs de p38 mitogen-activated kinase
PL2331547T3 (pl) 2008-08-22 2015-01-30 Novartis Ag Związki pirolopirymidynowe jako inhibitory CDK
RS54506B1 (sr) 2008-09-02 2016-06-30 Novartis Ag Derivati pikolinamida kao inhibitori kinaza
NZ597379A (en) 2009-06-29 2014-04-30 Agios Pharmaceuticals Inc Therapeutic compounds and compositions
CN103703531B (zh) 2011-05-31 2016-04-06 利纳克有限公司 致动器
JP2014237589A (ja) 2011-09-28 2014-12-18 日本曹達株式会社 環状アミン化合物および有害生物防除剤
US10434099B2 (en) 2016-09-22 2019-10-08 The National Institute for Biotechnology in the Negev Ltd. Methods for treating central nervous system disorders using VDAC inhibitors
EP3736272A1 (fr) 2015-09-14 2020-11-11 The National Institute for Biotechnology in the Negev Ltd. Nouveaux dérivés de pipérazine et pipéridine, leur synthèse et utilisation associée pour inhiber l'oligomérisation de vdac, l'apoptose et le dysfonctionnement mitochondrial
EP3199156A1 (fr) 2016-02-01 2017-08-02 Heinrich-Heine-Universität Düsseldorf Utilisation d'antagonistes du transporteur de la glycine 1 comme analgésiques du systeme nerveux central
JP6923138B2 (ja) 2016-06-30 2021-08-18 国立研究開発法人理化学研究所 新規化合物又はその薬理学的に許容される塩
US20210130291A1 (en) 2016-12-22 2021-05-06 The National Institute for Biotechnology in the Negev Ltd. Methods for treating diabetes using vdac1 inhibitors
US11377436B2 (en) 2017-07-12 2022-07-05 The Brigham And Women's Hospital, Inc. EAAT2 enhancing molecules
EP3697772A1 (fr) 2017-10-17 2020-08-26 Merck Patent GmbH Composés inhibiteurs de pyrimidine tbk/ikk et leurs utilisations
KR102695210B1 (ko) 2018-06-05 2024-08-13 크리네틱스 파마슈티칼스, 인크. 멜라노코르틴 아형-2 수용체(mc2r) 길항제 및 이의 용도
JP7657792B2 (ja) * 2019-11-07 2025-04-07 クリネティックス ファーマシューティカルズ，インク． メラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用
PT4077307T (pt) 2019-12-18 2025-06-03 Crinetics Pharmaceuticals Inc Antagonistas do recetor de subtipo 2 da melanocortina (mc2r) à base de piperidina gem-dissubstituída e suas utilizações
US12466829B2 (en) 2019-12-23 2025-11-11 Crinetics Pharmaceuticals, Inc. Spirocyclic piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof

Also Published As

Publication number Publication date
JP2023509310A (ja) 2023-03-08
DK4077307T3 (da) 2025-05-26
AU2020407016A1 (en) 2022-07-07
FI4077307T3 (fi) 2025-05-25
CA3164117A1 (fr) 2021-06-24
EP4077307A4 (fr) 2024-01-17
CN115335369B (zh) 2024-07-02
US12492181B2 (en) 2025-12-09
IL293941A (en) 2022-08-01
PT4077307T (pt) 2025-06-03
JP7672406B2 (ja) 2025-05-07
ES3031394T3 (en) 2025-07-08
HUE071813T2 (hu) 2025-09-28
EP4077307B1 (fr) 2025-03-12
EP4556067A3 (fr) 2025-07-30
IL293941B2 (en) 2025-11-01
EP4556067A2 (fr) 2025-05-21
PL4077307T3 (pl) 2025-07-14
WO2021126693A1 (fr) 2021-06-24
EP4077307A1 (fr) 2022-10-26
SI4077307T1 (sl) 2025-07-31
US20230135560A1 (en) 2023-05-04
IL321386A (en) 2025-08-01
JP2025124630A (ja) 2025-08-26
MD4077307T2 (ro) 2025-09-30
BR112022012033A2 (pt) 2022-10-11
MX2022007439A (es) 2022-07-19
KR20220129553A (ko) 2022-09-23
CN115335369A (zh) 2022-11-11
IL293941B1 (en) 2025-07-01

Similar Documents

Publication Publication Date Title
MA58049B1 (fr) Antagonistes du récepteur du sous-type 2 de la mélanocortine (mc2r) à pipéridine à double substitution gem et leurs utilisations
MA53665B1 (fr) Agonistes du récepteur farnésoïde x et leurs utilisations
MA51625B1 (fr) Procédé de production de modulateurs de somatostatine
PH12022550359A1 (en) Nonpeptide somatostatin type 5 receptor agonists and uses thereof
MA64509B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA64121B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA40290A1 (fr) Agents immunorégulateurs
MA47043A1 (fr) Composés indole carboxamides utiles comme inhibiteurs de kinase
MA34474B1 (fr) Agonistes de gpr40
MA30462B1 (fr) Composes de pyridylamide antagonistes des canaux calciques de type t
MA29931B1 (fr) Inhibiteurs de la proteine d'activation de la 5-lipoxygenase (flap)
EP4603142A3 (fr) Antagonistes du récepteur du sous-type 2 de la mélanocortine à base de pipéridine spirocyclique (mc2r) et leurs utilisations
MA30339B1 (fr) Azolopyrimidines inhibitrices de l'activite du recepteur cannabinoïde 1
MA52288B1 (fr) Modulateurs d'enzymes de modification de méthyle, compositions et utilisations de ceux-ci
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA40041A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA28660B1 (fr) Composes et compositions en tant que modulateurs de ppar
MA30906B1 (fr) Composes et compositions en tant quinhibiteurs des proteines kinases
MA49947B1 (fr) Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes
MA52492B1 (fr) Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés
MA35460B1 (fr) Composés et compositions en tant qu'inhibiteurs de kinase c-kit
MA47392B1 (fr) Bis-octahydrophénanthrène carboxamides et leurs conjugués protéiques
MA27997A1 (fr) Composes et compositions inhibiteurs de l'activite du recepteur tyrosine kinase
TN2012000073A1 (fr) Derives des l-(piperidine-4-yl) pyrazole servant de modulateurs de gpr119
MA33604B1 (fr) Composés et compositions en tant qu'inhibiteurs de protéine kinase